Advances in understanding the processes underlying brain neurodegeneration have allowed lots of new treatment and prevention strategies to begin to flourish. Several presentations at the 2024 Alzheimer’s & Parkinson’s Diseases Conference recently held in Lisbon reflect that eyes are now on some individuals who, despite showing pathological signs in their brains, stay cognitively healthy across several endogenous mechanisms of resilience. Read More
Sangamo Therapeutics Inc. has reported data from nonhuman primate (NHP) studies showing the potential of its proprietary AAV capsid variant, STAC-BBB, as a neurotropic capsid when administered intravenously at clinically relevant doses. STAC-BBB outperformed results for other evaluated neurotropic capsid variants. Read More
Shanghai Henlius Biotech Inc.’s IND application for HLX-6018, a novel anti-glycoprotein-A repetitions predominant (GARP)/transforming growth factor-β1 (TGF-β1) monoclonal antibody (mAb), has received approval by China’s National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Mutations in the gene encoding calpain-3, CAPN3, are causative for autosomal recessive limb-girdle muscular dystrophy-1 (LGMDR1), a type of muscular dystrophy characterized by muscle weakening around the shoulders and hips for which there is currently no treatment. Read More
Genzyme Corp. (dba Sanofi Genzyme) has disclosed isoxazolidine compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis, among others. Read More
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology. Read More
Cascade Pharmaceuticals Inc. has synthesized thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of MASLD/NAFLD, hypothyroidism and more. Read More
Alterations in mitochondrial dynamics are hallmarks of Parkinson’s disease (PD) and other neurodegenerative disorders such as Alzheimer’s disease (AD). Read More
Xgene Pharmaceutical Pty Ltd., a subsidiary of Xgene Pharmaceutical Co. Ltd., has received approval in Australia to initiate a phase I trial of the selective TRPM8 blocker XG-2002 (RQ-00434739). Read More
Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive, HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis. Read More
Merck & Co. Inc. has announced plans to initiate clinical development of a new investigational multi-valent human papillomavirus (HPV) vaccine designed to provide broader protection against multiple HPV types. Read More
The H. Lee Moffitt Cancer Center and Research Institute has described cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammation and myotonic dystrophy type 1 disease. Read More
Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer. Read More
Imunon Inc. has filed an IND application with the FDA seeking clearance to begin a phase I study of IMNN-101 as a seasonal COVID-19 booster vaccine. Read More
